Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial).
Manjula Singh, Sindhu Joshi, Vikram Vohra, Rohit Sarin, Suchit Vasant Kamble, Banurekha Velayutham, Anant Mohan, Urvashi B Singh, Rakesh Kumar, Sanghamitra Pati, Manoranjan Pattnaik, Prasanta Raghab Mohapatra, Uma Shankar, Somashekar Narasimhaiah, Geeta Yadav, Syed Hissar, Rashmi Rodrigues, Abhijit Vasantrao Kadam, Paul Kumaran Paramasivam, Sailaja Kambhampati, Ariarathinam Newtonraj, Natarajan Alangudi Palaniappan, S Devarajulu Reddy, Sourin Bhuniya, Bijaya Kumar Mishra, Ashwini Shete, Luke Elizabeth Hanna, Dipendra Kumar Mitra, Samiran Panda, Randeep Guleria, Srikanth Tripathy, Neelam Roy, George D'Souza, S K Tripathy, Kiran Katoch, Ravindra M Pandey, Seema Sah, Manisha Kashyap, Vinay Telasey, Meenakshi Bakshi, Nitya Wadhwa, Abdul Mabood Khan, Raman R Gangakhedkar, Rajni Rani
BMJ 393 e085716
摘要
摘要
OBJECTIVE: To evaluate the safety and efficacy of VPM1002 and Immuvac in reducing the incidence of microbiologically confirmed tuberculosis (TB; pulmonary TB and extrapulmonary TB), development of latent TB infection, and immunogenicity. DESIGN: Phase 3 randomised clinical trial (PreVenTB trial). SETTING: 18 sites across six states of India. PARTICIPANTS: 12 717 healthy household contacts (aged ≥6 years) of patients with a smear positive TB test. INTERVENTIONS: Participants were randomly assigned in a 1:1:1 ratio (using block randomisation with variable sample size) to receive an intradermal injection of VPM1002, Immuvac, or placebo in both arms. After one month, a second dose was administered in one arm to 11 829 healthy participants. OUTCOME MEASURES: The primary outcome was efficacy against confirmed TB (pulmonary TB and extrapulmonary TB) over 38 months of follow-up. Secondary outcomes were development of latent TB infection, adverse and serious adverse events, efficacy in predefined age groups, and immunogenicity. Exploratory outcomes were efficacy when considering tuberculin skin test status, and post hoc analyses of efficacy in participants aged 6-14 and according to body mass index. RESULTS: 252 and 227 participants developed microbiologically confirmed TB in modified intention-to-treat and per protocol groups, respectively. The per protocol analysis showed 65 (1.68%), 80 (2.09%), and 82 (2.13%) participants developed TB in the VPM1002, Immuvac, and placebo groups, respectively. Of these, 12 (0.31%), 16 (0.42%), and 24 (0.62%) developed extrapulmonary TB in the VPM1002, Immuvac, and placebo groups, respectively. In the per protocol analysis, VPM1002 showed vaccine efficacy of 21.4% (95% confidence interval (CI) -8.9% to 43.2%), 19.5% (-14.6% to 43.4%), and 50.4% (0.8% to 75.2%) against all TB, pulmonary TB, and extrapulmonary TB, respectively. Immuvac showed vaccine efficacy of 33.2% (-25.9% to 64.5%) against extrapulmonary TB. VPM1002 and Immuvac showed vaccine efficacy of 64.9% (-2% to 90.1%) and 66.3% (1.9% to 90.5%) against extrapulmonary TB in participants with tuberculin skin test positivity. Both vaccines were well tolerated with mild local reactions in about a third of participants. VPM1002 and Immuvac induced Mycobacterium tuberculosis specific polyfunctional CD4+ T cells. Post hoc analyses showed vaccine efficacy of 64.6% (95% CI 16.3% to 85.1%) against all forms of TB, 62.1% (3.0% to 85.2%) against pulmonary TB, and 77.6% (-3.7% to 95.2%) against extrapulmonary TB in participants aged 6-14 years in the VPM1002 group. CONCLUSIONS: Both vaccines were safe but did not show any efficacy against all forms of microbiologically confirmed TB or pulmonary TB. VPM1002 showed considerable efficacy against extrapulmonary TB. Both vaccines showed efficacy against extrapulmonary TB in participants who had a positive tuberculin skin test. TRIAL REGISTRATION: Clinical Trials Registry India CTRI/2019/01/017026.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(5,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。